Tar­sus scores first FDA ap­proval for treat­ment of red, itchy eyes caused by mites

Tar­sus Phar­ma­ceu­ti­cals has se­cured the FDA’s first ap­proval to treat ir­ri­tat­ed eyes caused by tiny mites, a con­di­tion known as de­mod­ex ble­phar­i­tis.

The drug, to be mar­ket­ed as Xdemvy, is an eye drop for­mu­la­tion of the com­mon vet­eri­nary drug lotalin­er used to pre­vent tick and flea in­fes­ta­tions. Tar­sus’ ap­proval came a month be­fore its an­tic­i­pat­ed de­ci­sion date, and al­so marks a first for the small Cal­i­for­nia biotech launched in 2017 with a fo­cus on eye care.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER